Summary: In adults with overweight/obesity (BMI ≥27) and established atherosclerotic CVD, without diabetes, semaglutide 2.4 mg once weekly for median…
Browsing: PICO
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous…
Summary: In adults with type 2 diabetes and CKD (eGFR 25-75, UACR >100-5000 mg/g) on stable ACEi/ARB therapy, semaglutide 1.0…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) from pooled STEP-HFpEF trials, stratified by baseline NT-proBNP tertiles,…
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg)…
Summary: In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40…
Summary: In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater…
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials,…
Summary: In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly…
Summary: In adults with long-standing T2D inadequately controlled on current therapy, subcutaneous tirzepatide (dual GIP/GLP-1 agonist) in Phase 1 trial…